Annovis Bio Inc Cash Flow Conversion Efficiency
Annovis Bio Inc cash flow conversion efficiency. Based on the latest financial reports, Annovis Bio Inc (ANVS) has a cash flow conversion efficiency ratio of -2.883x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.01 Million) by net assets ($3.13 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Annovis Bio Inc (2009–2025)
Cash flow conversion efficiency of Annovis Bio Inc from 2009 to 2025. This chart illustrates how Annovis Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ANVS stock price and chart for real-time trading data and today's change.
Annovis Bio Inc Cash Flow Conversion Ratio Explained
Annovis Bio Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Annovis Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Annovis Bio Inc ranked by their cash flow conversion efficiency. Also see ANVS market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
I Yuan Precision Ind Co Ltd
TWO:2235
|
0.005x |
|
George Kent (Malaysia) Bhd
KLSE:3204
|
-0.045x |
|
Gigas Hosting S.A
MC:GIGA
|
0.389x |
|
DRGEM Corporation
KQ:263690
|
0.016x |
|
Source Rock Royalties Ltd
V:SRR
|
0.027x |
|
Sunndal Sparebank
OL:SUNSB
|
N/A |
|
Fleming Properties AB
ST:FLMNG
|
0.012x |
|
Kriti Nutrients Limited
NSE:KRITINUT
|
0.186x |
Annual Cash Flow Conversion Efficiency for Annovis Bio Inc (2009–2025)
The table below shows the annual cash flow conversion efficiency of Annovis Bio Inc from 2009 to 2025. Review free cash flow generation of Annovis Bio Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $16.85 Million | $-25.62 Billion | -1520.344x | +35.37% |
| 2024-12-31 | $9.31 Million | $-21.89 Billion | -2352.325x | -45718.55% |
| 2023-12-31 | $-7.75 Million | $-39.97 Million | 5.157x | +943.59% |
| 2022-12-31 | $28.32 Million | $-17.31 Million | -0.611x | -197.82% |
| 2021-12-31 | $44.49 Million | $-9.13 Million | -0.205x | +61.02% |
| 2020-12-31 | $7.54 Million | $-3.97 Million | -0.527x | -1047.67% |
| 2019-12-31 | $-8.58 Million | $-476.54K | 0.056x | -24.46% |
| 2018-12-31 | $-7.59 Million | $-558.61K | 0.074x | -4.67% |
| 2017-12-31 | $-6.97 Million | $-537.48K | 0.077x | +114.53% |
| 2012-12-31 | $2.66 Million | $-1.41 Million | -0.531x | -145.69% |
| 2011-12-31 | $13.93 Million | $-3.01 Million | -0.216x | -100.99% |
| 2010-12-31 | $16.49 Million | $-1.77 Million | -0.108x | +59.22% |
| 2009-12-31 | $1.48 Million | $-389.23K | -0.264x | -- |
About Annovis Bio Inc
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury… Read more